13 results on '"Nitz U"'
Search Results
2. Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes
3. Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay
4. P342 - ADAPTcycle – adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate risk HR+/HER2- early breast cancer
5. P231 Luminal subtypes vs. early Ki-67 response and Oncotype DX® in early breast cancer: WSG-ADAPT study
6. P246 Risk assessment by St.Gallen 2013 recommendation and Oncotype DX®: results from the WSG PlanB trial
7. P226 - Chemotherapy (CT) decision in node-positive (N+), ER+, early breast cancer (EBC) after new ASCO Guideline – evidence for the 21-gene Recurrence Score (RS) assay
8. P213 - Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes
9. P178 Prospective comparison of uPA/PAI-1, Ki-67 based molecular classification, Recurrence Score and clinical–pathological characteristics in hormone-receptor (HR) positive primary breast cancer: Pilot phase of the randomized WSG PlanB trial
10. 0155 ICE study: Ibandronate with or without capecitabine in elderly patients with early breast cancer
11. P75 Current status and results of the second toxicityanalysis of a WSG/AGO-Mamma Intergroup Phase III trial AM02 “Ec->Doc” for patients with primary breast cancer and 1-3 positive axillary lymph nodes
12. P90 Tandem versus single high dose chemotherapy (HDC)with haematopoietic stem cell support in patients with chemosensitive metastatic breast cancer (MBC): outcome parameters - results from a randomised multicenter phase III trial
13. WSG/AGO-Mamma phase III trial: First toxicity analysis of a German intergroup study for patients with primary breast cancer and 1–3 positive axillary lymph nodes. Comparison of six cycles FEC or CMF chemotherapy with four cycles EC followed by four cycles of docetaxel
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.